Top Page
MetaVia
(NASDAQ:MTVA)
MetaVia (MTVA) vs. SPDR S&P 500 ETF (SPY)
MetaVia Business Overview & Revenue Model
MetaVia Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -19.00K | -24.00K | -7.00K | -28.00K | -72.00K | -67.00K |
| EBITDA | -15.82M | -28.79M | -15.88M | -11.76M | -15.24M | -29.67M |
| Net Income | -14.82M | -27.59M | -12.47M | -13.97M | -15.28M | -29.68M |
Balance Sheet | ||||||
| Total Assets | 18.46M | 16.26M | 22.78M | 33.53M | 16.80M | 10.97M |
| Cash, Cash Equivalents and Short-Term Investments | 17.59M | 16.02M | 22.43M | 33.36M | 16.39M | 10.09M |
| Total Debt | 98.00K | 136.00K | 203.00K | 0.00 | 71.00K | 94.00K |
| Total Liabilities | 8.84M | 8.33M | 6.10M | 11.78M | 2.20M | 3.77M |
| Stockholders Equity | 9.62M | 7.93M | 16.68M | 21.75M | 14.60M | 7.20M |
Cash Flow | ||||||
| Free Cash Flow | -14.09M | -24.72M | -10.85M | -11.71M | -15.14M | -10.77M |
| Operating Cash Flow | -14.09M | -24.71M | -10.80M | -11.71M | -15.13M | -10.76M |
| Investing Cash Flow | -2.00K | -8.00K | -50.00K | 8.00K | -586.00K | 69.00K |
| Financing Cash Flow | 8.57M | 18.30M | -80.00K | 28.68M | 22.03M | 6.86M |
MetaVia Technical Analysis
MetaVia Risk Analysis
MetaVia Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $17.81M | -0.22 | -54.40% | ― | ― | 18.73% | |
48 Neutral | $27.75M | -2.06 | -21.17% | ― | 12.71% | 79.93% | |
46 Neutral | $7.18M | -0.21 | -168.18% | ― | ― | 71.57% | |
45 Neutral | $17.61M | -0.44 | -355.80% | ― | ― | -273.84% |
MetaVia Corporate Events
On January 15–16, 2026, MetaVia Inc. completed an underwritten public offering of Class A and Class B units, consisting of common stock, pre-funded warrants and Series C and Series D common warrants, raising approximately $7.7 million in net proceeds after discounts and expenses from gross proceeds of about $8.1 million. The transaction, led by Ladenburg Thalmann & Co. Inc., included full exercise of the underwriter’s over-allotment option and established a package of fixed-price, immediately exercisable warrants, some of which are subject to beneficial ownership limits and potential future callability tied to positive Phase 1b Part III data for DA-1726; MetaVia plans to deploy the capital for working capital and general corporate purposes, notably to advance clinical development of DA-1726 for obesity, reinforcing its funding base and strategic focus in the competitive cardiometabolic drug development arena.
The most recent analyst rating on (MTVA) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
On January 5, 2026, MetaVia reported positive, statistically significant data from the extended eight-week, non-titrated 48 mg multiple ascending dose cohort of its Phase 1 clinical trial of DA-1726 in obese but otherwise healthy adults, highlighting robust early weight loss, strong metabolic improvements and direct hepatic effects. Patients receiving DA-1726 achieved an average 9.1% (21.2 lb) weight loss, a 9.8 cm reduction in waist circumference, a 12.3 mg/dL drop in fasting glucose and a 23.7% reduction in liver stiffness by Day 54, with no treatment-related discontinuations and only mild to moderate gastrointestinal events, underscoring a favorable safety and tolerability profile and reinforcing DA-1726’s potential to emerge as a differentiated, best-in-class GLP-1/glucagon dual agonist in the increasingly competitive obesity and metabolic disease market.
The most recent analyst rating on (MTVA) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
On May 29, 2025, MetaVia Inc. was notified by Nasdaq that it was not in compliance with the exchange’s $1.00 minimum bid price requirement after its shares traded below that threshold for 30 consecutive sessions, prompting the company on November 7, 2025 to seek, and on November 26, 2025 to receive, a 180‑day extension to May 26, 2026 to cure the deficiency. The company subsequently regained compliance when its stock closed at or above $1.00 for 10 straight business days from December 5 to December 18, 2025, leading Nasdaq on December 19, 2025 to confirm that MetaVia once again met the minimum bid price standard and that the listing matter was closed, removing a near‑term risk to its continued trading on the exchange.
The most recent analyst rating on (MTVA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
On December 2, 2025, MetaVia Inc. announced a 1-for-11 reverse stock split of its common stock, effective December 4, 2025, to comply with Nasdaq’s listing requirements. This decision, approved by the stockholders on June 30, 2025, reduces the number of outstanding shares from approximately 25.4 million to 2.3 million, while maintaining the authorized shares at 100 million. The reverse split will adjust the conversion and exercise prices of stock options and warrants proportionately, with fractional shares being rounded down and compensated in cash. The common stock will continue trading under the symbol ‘MTVA’ with a new CUSIP number.
The most recent analyst rating on (MTVA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
On May 29, 2025, MetaVia Inc. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its stock price had been below $1.00 for 30 consecutive trading days. The company requested a 180-day extension on November 7, 2025, to regain compliance, planning to potentially implement a reverse stock split to meet the requirement.
The most recent analyst rating on (MTVA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
On November 7, 2025, MetaVia Inc. announced positive results from its Phase 2a clinical trial of vanoglipel (DA-1241), a GPR119 agonist, as a potential treatment for MASH. The trial demonstrated vanoglipel’s ability to improve glucose control, liver health, and plasma lipidomic profiles after 16 weeks of treatment, highlighting its potential to address both hepatic and metabolic components of MASH. The data, presented at the AASLD The Liver Meeting® 2025, showed significant reductions in HbA1c, liver inflammation, and fibrosis, reinforcing vanoglipel’s potential as a monotherapy and combination therapy for MASH and related metabolic disorders.
The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
On November 6, 2025, MetaVia Inc. released an updated corporate presentation detailing its ongoing clinical trials and future milestones. The company is making significant progress with its DA-1726 and Vanoglipel (DA-1241) candidates, showing promising results in weight loss and glucose control, which could enhance its market position. MetaVia is also planning further clinical trials and regulatory submissions, potentially increasing shareholder value and impacting the treatment landscape for obesity and MASH.
The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.